Skip to Main Content
IBM System Storage Ideas Portal


This portal is to open public enhancement requests against IBM System Storage products. To view all of your ideas submitted to IBM, create and manage groups of Ideas, or create an idea explicitly set to be either visible by all (public) or visible only to you and IBM (private), use the IBM Unified Ideas Portal (https://ideas.ibm.com).


Shape the future of IBM!

We invite you to shape the future of IBM, including product roadmaps, by submitting ideas that matter to you the most. Here's how it works:

Search existing ideas

Start by searching and reviewing ideas and requests to enhance a product or service. Take a look at ideas others have posted, and add a comment, vote, or subscribe to updates on them if they matter to you. If you can't find what you are looking for,

Post your ideas
  1. Post an idea.

  2. Get feedback from the IBM team and other customers to refine your idea.

  3. Follow the idea through the IBM Ideas process.


Specific links you will want to bookmark for future use

Welcome to the IBM Ideas Portal (https://www.ibm.com/ideas) - Use this site to find out additional information and details about the IBM Ideas process and statuses.

IBM Unified Ideas Portal (https://ideas.ibm.com) - Use this site to view all of your ideas, create new ideas for any IBM product, or search for ideas across all of IBM.

ideasibm@us.ibm.com - Use this email to suggest enhancements to the Ideas process or request help from IBM for submitting your Ideas.

Status Submitted
Created by Guest
Created on Nov 22, 2026

A Long-Acting Injectable PrEP Adherence Record

PROBLEM: Daily PrEP fails when daily pills are missed, and the people most at risk are often the people least able to keep a daily routine. Without a record of the long-acting option — its schedule, its initiation, and who it is approved for — adherence is treated as a personal failure instead of a design problem.

SOLUTION: An injectable-PrEP adherence record that logs the long-acting schedule — two initiation injections one month apart, then one injection every two months — with the weight threshold and the approval date, so adherence is measured against the schedule the medicine was designed for.

EVIDENCE BASIS: REPORTED — Apretude (cabotegravir, long-acting injectable): December 20, 2021 — first injectable PrEP; two initiation injections one month apart, then every two months; approved for adults/adolescents weighing ≥77 lb (35 kg) (F22). Graded REPORTED, not DOCUMENTED: corroborated across multiple reliable sources, but no FDA press-release page was opened in this session. This draft claims the schedule only, never an adherence outcome.

Idea priority Low